Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab in second-line hepatocellular carcinoma
NCT01140347Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2010
- Primary completion
- Mar 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of ramucirumab in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Started Oct 2010; status: completed.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01140347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01140347.